Vertex to Buy Crinetics for $10 Billion, Crinetics Shares Surge 99%
VRTX•Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion in an all-cash deal, sending Crinetics shares up roughly 99% in premarket trading. The transaction expands Vertex’s rare disease pipeline and strengthens its position in endocrine therapies by adding Crinetics’ lead clinical programs to its portfolio.
1. Acquisition Details
Vertex will pay $10 billion in cash to acquire Crinetics in a buyout that values Crinetics at a roughly 99% premium to its premarket share price. The deal covers all outstanding Crinetics shares and is expected to close by year-end pending regulatory approval.
2. Share Reaction
Crinetics shares jumped by approximately 99% in premarket trading on the announcement, while Vertex shares rose about 0.3% ahead of the opening bell. The sharp move reflects investor enthusiasm for the strategic fit and potential near-term revenue contributions from Crinetics’ pipeline.
3. Strategic Rationale
The acquisition enhances Vertex’s rare disease portfolio by adding Crinetics’ lead clinical programs targeting endocrine disorders. It accelerates Vertex’s diversification beyond cystic fibrosis and broadens its development pipeline with novel therapeutic candidates.
